Hemcheck´s Newsletter - April 2020

Welcome to the April newsletter from Hemcheck

April was a very positive month in many aspects for Hemcheck, even though the ongoing SARS-CoV-2 pandemic continue to impact our work through cancelled or postponed trade fairs, customer meetings and user tests. We are continuously working on developing the company at all levels and we were very happy to announce two new agreements during the month, with SYNLAB and ANTISEL. Important milestones in our commercialization efforts.

In addition to the above, I get many questions if the pandemic could bring some opportunities for Hemcheck. So far, we do not have something concrete to report but we are of course looking into potential opportunities and if we can support the healthcare system in any way.

In this newsletter you can read more about the two agreements, as well as our newly released annual report for 2019 and upcoming events.

Enjoy the reading!
Joen Averstad, CEO

Subscription agreement with SYNLAB - first order within primary care

Hemcheck signed a subscription agreement with SYNLAB Sverige AB regarding delivery of one reader and one-time tests (v-Test) for usage within training and occupational health services.

-It is incredibly positive that we have a first customer within primary care, and more so given its SYNLAB which is a large global company active in 40 countries.

The two fields of usage are interesting:

Training is an interesting field since there is currently no other technology that can give the same direct feedback that we can give healthcare staff when drawing blood. By having the direct feedback it’s much easier to make the connection between own actions and the risk of a hemolyzed blood sample.

Occupational health services are also interesting. When healthcare staff travel to companies and perform blood sampling, its highly costly with hemolyzed blood samples, since it forces them to go back for additional blood sampling. It’s also a higher quality service for the companies that SYNLAB in this case provides, says Joen Averstad, CEO of Hemcheck.

Read more!

Distribution agreement signed with ANTISEL regarding Greece and Cyprus

Hemcheck signed a 26-month long exclusive distribution agreement with ANTISEL, one of the leading distributors of medical equipment in Greece and Cyprus. The agreement is set to start on May 1.

-After the study at Capio S:t Göran, which showed good results, we have started to discuss distribution agreements, initially in countries that approve CE marking but where we currently do not have good opportunities to act on our own. We believe ANTISEL is a good match for us in Greece and Cyprus and we will continue to look for other potential partnerships in other geographies, says Joen Averstad, CEO of Hemcheck.

Read more!
Antisel better

Annual report for 2019

We released our annual report for 2019 on April 16. 2019 was an important year and we want to take Hemcheck to the next level in 2020.

Read more!

Calendar of upcoming events

May 7, Interim report Q1
May 14, Annual general meeting

Contact us
Hemcheck Sweden AB
Karlstads universitet
Universitetsgatan 2
651 88 Karlstad